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Covariant perfusion patterns provide clues to the origin of
cognitive fluctuations and attentional dysfunction in Dementia
with Lewy bodies
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ABSTRACT
Background: Fluctuating cognition (FC), particularly in attention, is a core and defining symptom in dementia
with Lewy bodies (DLB) but is seen much less frequently in Alzheimer’s dementia (AD). However, its
neurobiological origin is poorly understood. The aim of our study was therefore to characterize perfusion
patterns in DLB patients that are associated with the severity and frequency of FC as measured both clinically
and using objective neuropsychological assessments.
Methods: Spatial covariance analyses were applied to data derived from single photon emission computed
tomography (SPECT) HMPAO brain imaging in 19 DLB and 23 AD patients. Patients underwent clinical
assessment of their FC and cognitive function as well as objective testing of their attention.
Results: Covariant perfusion principal components (PCs) were not associated with either FC or cognitive or
attentional measures in AD. However, in DLB patients, the second PC (defined as DLB-cognitive motor
pattern, DLB-PCI2) which was characterized by bilateral relative increases in cerebellum, basal ganglia,
and supplementary motor areas and widespread bilateral decreases in parietal regions, positively correlated
with poorer cognitive function, increased FC and worse attentional function measured both clinically and
neurophysiologically (p < 0.05) as well as with the severity of bradykinesia (p = 0.04).
Conclusions: FC in DLB appears distinct from those seen in AD, and likely to be driven by internal
neurobiological perturbations in brain circuitry as evidenced using spatial covariance analyses of cerebral
perfusion. FC and certain aspects of attentional dysfunction in DLB may, in part, depend upon both
distributed motor and non-motor networks.
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Introduction
Dementia with Lewy bodies (DLB) is the second
most common form of degenerative dementia
in older adults accounting for 15%–20% of
neuropathologically defined cases.
A core symptom of DLB is that of fluctuating
cognition (FC), which can affect up to 90% of
patients (McKeith et al., 2005). Clinically, these
spontaneous alterations in arousal, attention, and
cognition can have significant impacts on patient
function (Ballard et al., 2001). Qualitatively, FC
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in DLB appears to be distinct from the less
frequently seen fluctuations in other dementias such
as Alzheimer’s disease (AD), with an interruption
of awareness which is often associated with
transient episodes of confusion and communicative
difficulties (McKeith et al., 2005). Remission
to near-normal cognitive function can occur
spontaneously in the absence of clear environmental
triggers, suggesting that FC in DLB is internally
driven in contrast to AD, where FC may be
more dependent upon changes in the environment
(Bradshaw et al., 2004).
Clinical assessment of FC can be performed
using a number of semi-standardized clinical
scales such as the clinical assessment of
fluctuations (CAF) scale (Walker et al., 2000a)
or the Mayo fluctuations Questionnaire (Ferman
et al., 2004). Objective measures of FC have
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included performance variability in attentional tasks
including the choice reaction time (CRT) (Walker
et al., 2000a). However, despite the prominence
and pervasiveness of FC in DLB, there is no clear
biomarker of FC and the underlying etiology of FC
in DLB is poorly understood.
DLB patients, on electroencephalography
(EEG), tend to display increased slow wave
activity posteriorly compared to AD patients
(Bonanni et al., 2008) and in DLB patients
the EEG frequency fluctuates in periodic
patterns, particularly posteriorly, in the delta–
theta/prealpha or theta/prealpha/alpha range with
these abnormalities positively correlating with
the frequency and severity of clinically observed
FC (Walker et al., 2000b). However, which
brain areas contribute to FC is unknown and
no obvious structural brain changes have been
associated with FC in DLB. Whitwell et al. (2007)
observed volume reductions in the hypothalamus
of DLB and they suggested this might relate to
altered arousal and attention in DLB although
this study did not make any direct link between
this structural change and the presence or severity
of FC. Rather it is likely that FC arises from
functional and network perturbations rather
than overt structural abnormalities. In support
of this, a recent functional blood-oxygen-level-
dependent (BOLD) resting state network analysis
found that reductions in functional connectivity
between right frontal and parietal in DLB
patients were associated with FC (Franciotti
et al., 2013). In addition, clinicopathological data
have demonstrated dopaminergic and cholinergic
changes in thalamic areas in DLB patients with
disturbed consciousness/arousal compared to those
without (Pimlott et al., 2006; Piggott et al., 2007)
and consistent with this finding is the observation
of increased FC and increased thalamic perfusion
on HMPAO single photon emission computed
tomography (SPECT) in Lewy body dementia
patients (O’Brien et al., 2005). In particular, the
cholinergic system which is widely distributed in
brain and differentially more affected in DLB than
AD may have a role; pharmacological evidence
has demonstrated that anticholinergic drugs can
induce a symptom profile of altered arousal (Perry
et al., 1999) that is similar to FC seen in DLB and,
by contrast, cholinesterase inhibitors (CHEI) can
significantly improve FC and attentional function
in DLB (McKeith et al., 2000; Wesnes et al., 2002).
Taking these data together with known EEG
changes in DLB, we hypothesized that FC is likely
to be associated with spatially distributed networks,
perhaps modulated by cholinergic function, rather
than focally located in any single brain structure.
One way to test this hypothesis is the application of
multivariate network approaches and one specific
technique is that of voxel spatial covariance analysis
(SCA) called scaled subprofile model (Gene and
Alexander, 1994), which is an extension of principal
component analysis (PCA), which generate a series
of PCA eigenimages of brain uptake representing
significant sources of variance in the data that may
also reflect specific disease characteristics.
Use of these analyses applied to positron
emission tomography (PET) and SPECT images is
not without precedent in Lewy body disease (Eckert
et al., 2007b): in Parkinson’s disease (PD), SCAs
have helped characterize the relationship between
disease-specific covariant metabolic networks and
cognitive andmotor dysfunction as well as providing
a biometric probe for therapeutic response, for
example, to a dopaminergic medication (Eckert
et al., 2007a; Hirano et al., 2009). In addition, more
recently we have shown that amultivariate approach
can usefully discriminate between DLB and AD
with high sensitivity and specificity (Colloby et al.,
2013).
In the present study, we applied SCA toHMPAO
perfusion SPECT data in a cohort of DLB and
AD patients who underwent comprehensive clinical
and cognitive assessments and our primary aim was
to identify any spatial covariant perfusion principal
component images (PCIs) related to FC, attentional
dysfunction and, in DLB, to the severity of
Parkinsonism given the prior evidences of covariant
networks associated with motor dysfunction in PD
(Eckert et al., 2007a). If such PCIs were present
and associated with FC, our secondary aim was to
clarify if these patterns were differentially expressed
in those taking CHEI compared to those not on
these agents.
Methods
Patients
Dementia patients (23 AD and 19 DLB)
were recruited from a local community-dwelling
population of patients who had been referred
to geographically based old age psychiatry and
neurology services. The study was approved by
the local research ethics committee and UK De-
partment of Health’s Administration of Radioactive
Substances Advisory Committee (ARSAC). All
patients, as well as the nearest relative for patients,
gave informed written consent.
Patients underwent detailed physical, neurolo-
gical, and neuropsychiatric examinations, which
included history, mental state, and physical exam-
ination. Investigations included routine hematology
and biochemistry screening, thyroid function tests,
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syphilis serology, vitamin B12 and folate levels,
chest X-ray, and head CT scan.
Diagnosis of dementia type was made inde-
pendently by consensus between three experienced
senior clinicians using NINCDS-ADRDA criteria
for AD (McKhann et al., 1984) and the
international workshop criteria for DLB (McKeith
et al., 1996). Sixteen of the 19 DLB patients also
had clinical SPECT Fluoropropyl-Carbomethoxy-
Iodophenyl-Tropane (FP-CIT) dopamine trans-
porter scans to assist with diagnosis (abnormal in
12/16). In addition, neuropathological confirmation
of diagnosis according to international criteria was
available in four out of 23 AD patients (four definite
AD) and in seven out of 19 DLB patients (six
definite DLB and one mixed DLB/AD pathology).
FP-CIT imaging was abnormal in 6/7 of the
neuropathologically confirmed DLB cases.
Assessments
Patients underwent a range of clinical assessments.
Primary clinical variables in patients which were
used to identify salient covariant perfusion networks
associated with cognitive and attentional func-
tion included: Cambridge Cognitive Examination
(CAMCOG), a marker of global cognitive function;
Unified Parkinson’s Disease Rating Scale Part
III (UPDRS), a global marker of the severity
of extrapyramidal signs; the CAF, as a clinical
measure of FC (Walker et al., 2000a); CRT, a
measure of information processing speed in a visual
stimulus discrimination task and the variability
(standard deviation) of this task (CRT(SD)) as
an objective measure of FC (Walker et al.,
2000a). Secondary clinical variables which were
examined in terms of correlation with covariant
perfusion networks included the Mini-Mental State
Examination (MMSE), the CAMCOG subscales
scores of orientation, attention, and calculation
(domains dependent on attentional function); and
the bradykinesia subscale score from the UPDRS
given that bradykinetic-rigid motor profile (rather
than tremor dominant) is more typically seen in
DLB (Aarsland et al., 2001).
99mTc-exametazime (HPMAO) SPECT
imaging
Patients were scanned using a triple-headed rotating
gamma camera (Picker 3000XP) fitted with a
high-resolution fan-beam collimator, approximately
10 minutes after a bolus intravenous injection
of 500 MBq of 99mTc-exametazime (Ceretec,
GE Healthcare, also referred to as HMPAO, GE
Healthcare, Buckinghamshire, UK). One hundred
and twenty 15-second views over a 360-degree orbit
were acquired on a 128 × 128 matrix with a pixel
and slice thickness of 3.5 mm. Imaging time was 30
minutes. Images were reconstructed using ramp-
filtered backprojection with a Butterworth filter
(order 13, cut-off 0.2 cycles cm−1), then resampled
to a 64 × 64 matrix containing 4.0 mm cubic
voxels. Axial resolution was 12mm full width at half
maximum (FWHM) and the reconstructed images
were corrected for gamma-ray attenuation using
Chang’s algorithm (uniform attenuation coefficient,
μ = 0.11 cm−1). Scatter correction was not applied.
Spatial pre-processing
All images were spatially normalized using an affine
transform (12 parameters) to match a 99mTc-
exametazime SPECT template in standard MNI
(Montreal Neurological Institute: http://www2.bic.
mni.mcgill.ca/) space using FMRIB’s linear image
registration tool (FLIRT: http://www.fmrib.ox.ac.
uk/fsl/flirt/index.html). Generation of the template
image has been previously described (Colloby et al.,
2008). Subsequent to this, images were visually
inspected to ensure accuracy of registrations. A 16-
mm FWHM 3DGaussian filter was then applied to
the registered scans, producing spatially smoothed
images. Finally, scans were intensity scaled to their
mean whole-brain uptake defined from a SPECT
binary mask image.
Multivariate spatial covariance analysis
Voxel-based SCA was applied separately to the pre-
processed images of the AD and DLB dementia
cohorts using the generalized covariance analysis
software suite (http://www.nitrc.org/projects/gcva_
pca/) (Habeck et al., 2005). A SPECT binary
mask image defined the brain volume subspace
for voxel-wise analyses and this generated a series
of eigenimages/PCIs that were organized in a
decreasing order of variance for each subsequent
eigenimage. Voxels participating in each eigenimage
may have either positive or negative weights, where
the weights express the strength of interaction
between voxels that contribute to the eigenimage.
Voxels with positive and negative weighting can be
interpreted as exhibiting concomitant increased and
decreased activity/blood flow, respectively. Once
calculated, eigenimage weights were fixed and equal
for all patients within the respective dementia
cohort. The degree to which a patient expressed
each eigenimage was by means of a subject scaling
factor SSFi, where a higher SSF score represents
more concurrent increased flow of voxels with
positive weights and more concurrent decreased
flow of voxels with negative weights.
Disease-specific individual SSF expressions on
each eigenimage, which contributed more than
10% of the variance, were correlated against the
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Table 1. Demographic and clinical characteristics of patients
AD DLB P-VALUE
............................................................................................................................................................................................................................................................................................................................
N 23 19 –
Gender (M:F) 11:12 12:7 0.37∗
Age (yrs) 78.8 ± 6.0 76.2 ± 8.0 0.25
MMSE (max. 30) 17.5 ± 4.8 16.2 ± 5.6 0.77
CAMCOG (max. 107) 59.8 ± 15.8 63.8 ± 13.9 0.40
UPDRS III (max. 108) 5.8 ± 6.1 23.2 ± 13.8 <0.001
Disease duration (months) 33.2 ± 18.9 33.6 ± 26.0 0.96
CAF 0.3 ± 1.0 3.7 ± 3.5 <0.001
Choice reaction time (CRT) 6.41 ± 0.23 6.93 ± 0.49 <0.001
Choice reaction time standard deviation (CRT(SD)) 5.10 ± 0.48 5.93 ± 0.74 <0.001
CHEI use (yes:no) 2:17 5:14 0.41∗
L-dopa or equivalent use (yes:no) 0:23 2:17 N/A
Values expressed as (mean ± 1 standard deviation).
∗χ2 value (df = 1).
AD = Alzheimer’s disease; DLB = dementia with Lewy bodies; MMSE = Mini-Mental State Examination; CAMCOG = Cambridge
Cognitive Examination; UPDRS III = Unified Parkinson’s Disease Rating Scale (motor subsection); CAF = Clinical assessment of
fluctuations; CHEI = cholinesterase inhibitor.
Note that reaction time data (milliseconds) reported have been log transformed.
primary outcome measures; PCIs with significant
correlations with at least one of these parameters
were then analyzed further against our secondary
measures.
Eigenimages were Z-thresholded at |Z|  1.64
(p  0.05), and the derived PCI topographic
perfusion networks also underwent bootstrap
resampling to determine significant local maxima
which were contributory to the overall network.
Localization of network regions in PCIs, which were
significantly associatedwith clinical parameters, was
further assessed using the MNI brain atlases within
fslview (http://fsl.fmrib.ox.ac.uk/fsl/fslview/).
Statistics
Patient expressions of the perfusion PCs were
exported into the Statistical Package for Social Sci-
ences software (SPSS ver. 19.0, http://www-01.ibm.
com/software/analytics/spss/products/statistics/) for
analysis. Normality of continuous variables was
assessed using visual inspection of histograms and
application of the Shapiro–Wilk test. Demographic
and clinical data between groups were compared
using student t-tests. In the case of reaction time
variables, these data were positively skewed and
thus were log-transformed to allow for parametric
analyses. Categorical data were analyzed using χ2
tests.
Correlations between imaging data and clinical
variables were determined using Pearson r. Con-
sideration was then given to potential confounders
including age, sex, CHEI use (score 0 = no use,
score 1 = use of CHEI), and UPDRS scores (for
reaction-time based tasks), if they correlated with
imaging and clinical variables of interest (threshold
p < 0.10). The confounder of disease severity
was examined by considering duration of illness.
In addition for measures of FC and attention
(clinical and objective), the effect of global cognitive
impairment (MMSE score) was also examined as
a covariate. Potential confounder variables (p <
0.10) were then entered into a stepwise multiple
regression models to assess their effect on the
relationship between any PCI expression and
dependent variables.
Results
Patient demographic characteristics are reported
in Table 1. AD and DLB patients were broadly
matched in terms of age, gender, cognitive
impairment, disease duration, and CHEI use. As
expected, DLB patients had increased UPDRS
and CAF scores and more attentional impairments
compared to AD. CAF scores in DLB correlated
with the objective measures of attention (CRT, r =
0.47, p = 0.04; CRT(SD), r = 0.54, p = 0.02).
Disease-specific covariant perfusion patterns
Covariant perfusion PCIs were derived separately
for AD and DLB cohorts; the first two PCs
accounted for variance greater than 10% (AD-
PCI1, 18.7% and AD-PCI2, 13.9%; Figures 1a
and b). In the DLB cohort, the first two PCs
similarly accounted for variance greater than
10% (DLB-PCI1, 16.7% and DLB-PCI2, 15.3%;
Figures 1c and d). AD-PCI1 and DLB-PCI1
demonstrated shared covariance perfusion patterns
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Figure 1. Covariant perfusion patterns in Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB) cohort contributing more than
10% of the variance superimposed onto structural MRI template images. Images show concomitant increase (red) and decrease (blue)
regional cerebral blood flow (thresholded at |Z| 1.64, p 0.05). PCI= principal component image. Note only DLB-PCI2 correlated with
clinical variables (boxed in red).
in selected brain regions in bilateral thalami and
putamen (concomitant increases) as well as bilateral
precuneus and left occipital lobe (concomitant
decreases). Other regions specific to the AD-PCI1
pattern were bilateral pre- and post central gyrus,
cerebellum (covariant decreases in perfusion), and
left temporal lobe (covariant increases). Likewise,
regions specific to the DLB-PCI1 pattern included
anterior cingulate and bilateral caudate (covariant
increases). AD-PCI2, in contrast, exhibited an
approximate bilateral superior–inferior pattern
with concomitant increased perfusion in inferior
temporal and occipital lobe and concomitant
decreased perfusion in anterior cingulate and pre
and post central structures.
AD-PCI1, AD-PCI2, and DLB-PCI1 did not
correlate significantly with our primary clinical
variables (Table 2), and were therefore not analyzed
in further detail. However, DLB-PCI2 was
strongly associated with our primary cognitive,
attentional, and FC measures (CAMCOG, CRT,
CRT(SD), and CAF) and was therefore selected for
further investigation. Table 3 presents brain regions
having a significant contribution to the DLB-
PCI2 covariance pattern. Concomitant increased
perfusion was observed in motor networks,
parietal and temporo-parietal cortices bilaterally,
cerebellar hemispheres, particularly the midline and
Table 2. Pearson correlations between principal
component image (PCI) expression and primary
clinical variables
AD DLB
PCI1 PCI2 PCI1 PCI2
........................................................................................................................................................
CAMCOG 0.11 0.08 0.08 − 0.50∗
CAF 0.01 − 0.11 –0.34 0.59∗∗
CRT − 0.29 0.11 − 0.28 0.60∗∗
(CRT(SD)) − 0.30 0.16 − 0.24 0.62∗∗
UPDRS − 0.18 0.22 − 0.13 − 0.37
AD = Alzheimer’s disease; DLB = dementia with Lewy bodies;
CAMCOG = Cambridge Cognitive Examination; CAF = Clinical
assessment of fluctuations; CRT = choice reaction time; CRT(SD)
= choice reaction time variability (standard deviation); UPDRS III
= Unified Parkinson’s Disease Rating Scale (motor subsection).
∗p < 0.05; ∗∗p < 0.01.
vermis, extending into the midbrain and bilateral
supplementary motor areas (SMA) and putamen
(although relatively smaller on right compared
to left). Unilateral increases were also evident
in left lingual gyrus. Concomitant decreases also
occurred bilaterally in parietal cortex affecting
inferior parietal, angular gyri, and supramarginal
areas as well as in superior and middle temporal
cortices. There was also a suggestion that left
secondary visual areas were involved in the pattern.
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Table 3. Brain regions with significant contributions to the DLB cognitive motor pattern (DLB-PCI2). Regions
reported had significant clusters (p < 0.05) with a minimum of ten voxels per cluster with localization of
cortical and basal ganglia areas derived from Marsbar toolbox (MARSeille Boîte À Région d’Intérêt) and
brainstem areas from wfupickatlas
REGION (z SCORE  1.64) CLUSTER SIZE REGION (z SCORE  −1.64) CLUSTER SIZE
............................................................................................................................................................................................................................................................................................................................
Cerebellum_4_5_L 140 Angular_R 24
Cerebellum_4_5_R 36 Angular_L 45
Cerebellum_6_L 166 Occipital_Mid_L 14
Cerebellum_6_R 81 Parietal_Inf_L 85
Cerebellum_7_L 52 Parietal_Inf_R 21
Cerebellum_7_R 45 SupraMarginal_L 73
Cerebellum_Crus1_L 83 Temporal_Inf_R 14
Cerebellum_Crus1_R 111 Temporal_Mid_L 56
Fusiform_L 29 Temporal_Mid_R 27
Lingual_L 60 Temporal_Sup_L 36
Midbrain 42 Temporal_Sup_R 14
Parahippocampal_L 29
Pons 24
Putamen_L 42
Supp_Motor_Area_L 112
Vermis_10 14
Vermis_3 29
Vermis_4_5 63
Vermis_6 31
Vermis_7 24
Vermis_8 30
Vermis_9 17
Association between PCI2 expression in DLB
patients and clinical variables
DLB-PCI2 correlated significantly with a number of
the secondary clinical variables (Table 4). MMSE
as well as CAMCOG subscale scores correlated
negatively with the expression of DLB-PCI2,
although the CAMCOG executive subscale was not
significantly associated with DLB-PCI2.
DLB-PCI2 was positively associated with
UPDRS bradykinesia subscale score although not
with the overall UPDRS score.
EFFECT OF CONFOUNDER VARIABLES
A number of confounder variables (age, disease
duration, UPDRS, CHEI use, and MMSE scores)
were significantly associated with clinical measures,
although inclusion of these in a multivariate analysis
did not significantly affect the relationship between
DLB-PCI2 and the clinical variables in question
(Table 4). Nevertheless, we separately considered
the importance of CHEI use given its significant
known effect on attention and FC. Our data
confirmed (Supplementary Table 1, available as
supplementary material attached to the electronic
version of this paper at www.journals.cambridge.
org/jid_IPG) that DLB patients on CHEI had less
FC as measured on the CAF and faster CRT
and lower CRT(SD) (p  0.006). In contrast,
patients taking CHEI versus those not on these
agents had similar global and subscale cognitive
measures and Parkinsonism (p 0.26). Importantly
however, DLBs who were taking CHEIs had
significantly less positive expression of DLB-PCI2
compared to those who were not these agents (p =
0.003), despite the fact that the relationship
between DLB-PCI2 expression and our primary
clinical and objective measures of attention and FC
(CAF, CRT, and CRT(SD)) was not confounded
by CHEI use (Table 4).
Therefore, we hypothesized that DLB-PCI2
expression was acting as a mediator variable
between CHEI use and our primary measures of FC
and attentional function. Indeed, after controlling
for DLB-PCI2 expression, the partial correlation
between CHEI use and CAF, CRT, and CRT(SD)
was reduced to non-significance (r = −0.14,
p = 0.59; r = −0.13, p = 0.60; r = −0.16, p =
0.54, respectively), suggesting a strong mediation
role for the expression of DLB-PCI2 in modulating
CHEI use and improvements in CAF, CRT, and
CRT(SD).
Discussion
We found that in DLB patients, a single covariant
perfusion network was positively associated with
Covariant perfusion patterns in DLB 1923
Table 4. Univariate and multivariate associations between dementia with Lewy body (DLB) principal
component image (PCI) 2 and clinical variables. Values expressed as (mean± 1 standard deviation)
CLINICAL VARIABLE UNIVARIATE R P-VALUE
CLINICAL/DISEASE
COVARIATES (P < 0.10)
MULTIVARIATE
ANALYSIS
............................................................................................................................................................................................................................................................................................................................
Cognitive
MMSE −0.57 0.01 – –
CAMCOG (total)∗ −0.50 0.04 – –
CAMCOG (executive) −0.37 0.13 Age, r = –0.43, p = 0.08 F = 4.32, r = 0.60; age,
beta = –0.34; p = 0.03;
DLB-PCI2, beta = –2.45,
p = 0.06
CAMCOG (memory) −0.48 0.04 – –
CAMCOG (orientation) −0.58 0.009 –
– –
CAMCOG (attention) −0.54 0.02 – –
CAMCOG (calculation) −0.59 0.008 – –
Cognitive fluctuations
Clinical assessment of
fluctuations∗
0.59 0.009 CHEI, r = –0.46, p = 0.05 F = 8.86, r = 0.59; CHEI,
beta = –0.15, p = 0.59;
DLB-PCI2, beta = 2.07,
p = 0.008
Objective attention tests
Choice reaction time
(CRT)∗
0.60 0.007 Disease duration, r = 0.68,
p = 0.005; CHEI, r =
–0.47, p = 0.04; UPDRS,
r = 0.59, p = 0.008;
MMSE, r = –0.61, p =
0.008
F = 52.79, r = 0.98; disease
duration, beta = 0.01, p <
0.001; CHEI, beta = 0.05,
p = 0.62; UPDRS, beta =
0.01, p = 0.001; MMSE,
beta = –0.03, p = 0.02;
DLB-PCI2, beta = 0.16,
p = 0.004
Choice reaction time
standard deviation
(CRT(SD))∗
0.62 0.005 Disease duration, r = 0.48,
p = 0.07; CHEI, r =
–0.50, p = 0.03; UPDRS,
r = 0.64, p = 0.003;
MMSE, r = –0.67, p =
0.002
F = 24.90, r = 0.95; disease
duration, beta = 0.01, p =
0.05; CHEI, beta = 0.09,
p = 0.54; UPDRS, beta =
0.02, p = 0.009; MMSE,
beta = –0.06, p = 0.006;
DLB-PCI2, beta = 0.24
p = 0.02
Parkinsonism
UPDRS III motor subscale
score∗
0.36 0.13 – –
Bradykinesia subscale score 0.48 0.04 – –
∗Primary clinical variables of interest.
AD = Alzheimer’s disease; DLB = dementia with Lewy bodies; MMSE = Mini-Mental State Examination; CAMCOG = Cambridge
Cognitive Examination; UPDRS III = Unified Parkinson’s Disease Rating Scale (motor subsection); CHEI = cholinesterase inhibitor (for
regression purposes non-use score = 0, use of agent score = 1).
cognitive and attentional dysfunction as well
as clinically and objectively measured FC and
bradykinesia. This DLB-PCI2 network included
covariant activity in both motor (tendency to
increased activity) and associative parietal and
parieto-temporal areas (tendency to decreased
activity) bilaterally. No such networks were
evident in those with AD patients, reinforcing
the conclusion that FC and cognitive–attentional
dysfunction in DLB have a specific underlying
pathophysiological origin, which may relate, in part,
to activity in both posterior cortical and motor
system networks.
In contrast, PCI-1 in both DLB and AD,
and PCI-2 in AD did not associate with our
primary clinical variables. It may be that these
perfusion patterns relate to other disease factors
not measured in the present study. Certainly,
the PCI-1 in both DLB and AD demonstrated
perfusion changes which included periventricular
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regions and thus these PCIs may relate more to
the gross, structural, atrophic changes rather than
more nuanced, functional changes that associate
with clinical symptoms or cognition. In addition,
it is notable that the reported metabolic PCI which
most strongly related cognition in PD (see below)
was in fact the second and not the first PCI (Huang
et al., 2007), similar to our findings here.
DLB-PCI2: SIMILARITIES AND
DIFFERENCES COMPARED TO OTHER
COVARIANT LEWY BODY DISEASE
NETWORKS
In PD, two covariant PET-related metabolic net-
works have been reported including a Parkinson’s
disease-related pattern (PDRP) and a Parkinson’s
disease-related cognitive pattern (PDCP, Eckert
et al., 2007a; Huang et al., 2007). The former
correlates with the severity and duration of motor
symptoms in PD (Eidelberg et al., 1995; Lozza
et al., 2004; Asanuma et al., 2006) and the latter
is associated with neuropsychological performance
in non-demented PD and PD with mild cognitive
impairment (Lozza et al., 2004; Huang et al.,
2007). The PDRP is characterized by relative
increases in metabolic activity in pallidothalamic,
pontocerebellar, and motor cortical and SMA
metabolic activity with covariant decreases in lateral
premotor and posterior parietal areas. In contrast,
the PDCP shows increased metabolic activity in
the cerebellum and dentate nuclei with relative
decreases in the prefrontal and parietal cortex.
Both the PDRP and the PDCP in PD share
overlapping topology but are orthogonal in their
associations with motor and cognitive deficits. In
contrast, in the present data in DLB patients,
there was a convergence of some aspects of motor
deficit (bradykinesia) and cognitive deficits onto one
perfusion network. Differences between the DLB-
PCI2 and the PD-related metabolic networks in
terms of the topology and direction of covariance
may be explained by methodological differences
between SPECT perfusion and PET metabolic
imaging although given that univariate perfusion
and metabolic patterns are broadly similar in
DLB (Colloby et al., 2002, 2013; Abe et al.,
2003), this is less likely to be factor. Alternatively,
the differences between DLB-PCI2 and the PD
metabolic networks could be the result of the more
global and severe nature of the cognitive impairment
in DLB compared to PD (e.g. Huang et al. study
MMSE 28.3± 2.1 vs. MMSE 16.2± 5.6 in present
study), as well as intrinsic differences in motor
phenotype (e.g. Huang et al. (2007) study, UPDRS
was 34.3± 18 vs. 26.6± 15.3 in present study) and
levels of dopaminergic medication use between the
two diseases.
On the other hand, the DLB-PCI2 network
shared some topological characteristics seen in both
PD-related metabolic patterns including relative
SMA and cerebellar increases analogous to those
seen in the PDRP as well as decreases in parietal
areas which are evident in the PDCP. Therefore, a
unifying explanation for the overlap in some areas,
yet difference in others, between DLB-PCI2 and
the PD network patterns may be that the topology
of DLB-PCI2 represents the convergence of both
motor and cognitive deficits onto one network
after the development of more advanced cortical
Lewy body pathology although in the present study
while we did not see any association between
disease duration and DLB-PCI2 expression. A
proper analysis of covariant perfusion or metabolic
networks longitudinally in cohorts of early stage
DLB and PD patients who develop dementia would
need to be carried out to clarify this hypothesis.
DLB-PCI2 AND ASSOCIATION WITH
COGNITIVE MEASURES IN DLB
DLB-PCI2 expression negatively correlated in
DLB patients with global cognitive function
in terms of the MMSE and CAMCOG. In
addition, CAMCOG subscore scales of orientation,
attention, and calculation negatively correlated
with DLB-PCI2; these are all domains which
are dependent upon attentional function, thus
suggesting this is the main driver for the association
between cognitive dysfunction and DLB-PCI2
expression. Of note, there was no clear association
between DLB-PCI2 and the memory CAMCOG
subscale. This is not unsurprising given that the
topological distribution of DLB-PCI2 did not
include medial temporal lobe structures which
are more likely to be associated with deficits
in this subscore. However, there was no strong
association betweenDLB-PCI2 and the CAMCOG
executive subscale score and while this might be
explained by the relative lack of involvement of
the frontal lobe in the DLB-PCI2, controlling
for age improved the negative correlation between
the CAMCOG executive subscore and DLB-PCI2
expression (although this was still only a trend
association). This observation in conjunction with
the fact that there was no association between DLB-
PCI2 expression and age (r = −0.02, p = 0.95)
may tentatively suggest that both age and DLB-
PCI2 jointly affect executive function via similar
mechanisms e.g. a deterioration in frontostriatal
activity.
Nevertheless, revised versions of the CAMCOG
executive (or memory) subscores have been
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critiqued in terms of their validity (Kessels et al.,
2009) and a specific limitation of the present study
was that detailed neuropsychological testing of
executive function was not carried out which might
have helped elaborate more clearly what elements
of cognition and executive function (aside from
attention) were related (or not) to DLB-PCI2.
DLB-PCI2 AND ASSOCIATION WITH
COGNITIVE FLUCTUATIONS IN DLB
The observation that a lesion in one cortical
area does not necessarily lead to significant
alterations in arousal or consciousness supports
the conjecture that FC and arousal (Mesulam,
1981; Steriade, 2006) are unlikely to arise from
discrete topographic areas but rather are likely to
arise from a widely distributed and interconnected
network. The positive association between FC
clinically and the DLB-PCI2 corroborates this as
the multivariate nature of the applied SCA is
sensitive to dysfunctions across a distributed system
rather than specific nodal deficits.
Several nodes of the DLB-PCI2 receive
substantive cholinergic innervation including the
striatum, parietal cortex, and cerebellum and
thus a link between cholinergic function, activity
within the DLB-PCI2 network, and FC could be
hypothesized. In support of this, DLB patients on
CHEI displayed better reaction times on attentional
tasks and less FC than those not on these agents,
which is consistent with previous reports in the
literature (Wesnes et al., 2002), and mediation of
this effect appeared to be in part via DLB-PCI2.
However, we are cautious in our interpretation
given the cross-sectional nature of the study and
the fact that only five DLBs at the time of imaging
were on CHEI. In addition, it is feasible that the
association between CHEI and DLB-PCI2 as well
its association with FC and attentional measures
could be affected by a clinical treatment selection
bias, although one might expect those initiated on
CHEI to havemore cognitive impairment which did
not appear to be the case (Supplementary Table 1).
Other distributed cortical systems reliant on
different neurotransmitters may be responsible for
arousal and attention may be compromised and
contribute to the development of FC; in particular,
it has been posited that non-cholinergic systems
including dopamine (particularly in PDD) and
noradrenergic systems as well as structures that
mediate arousal and circadian function such as
the hypothalamus and midbrain may have a role
(Francis et al., 2006). It is notable that the
severity of bradykinesia, which is associated with
hypodopaminergic states correlated with DLB-
PCI2 expression. This with observation that DLB-
PCI2 incorporated the striatum might suggest a
dopaminergic role in certain aspects of attention
and FC in DLB, although we did not see any clear
association between UPDRS total scores and DLB-
PCI2 expression. Rather our data tend to favor the
established argument that cholinergic function has
a more predominant role with regard to attentional
function in DLB (Wesnes et al., 2002).
DLB-PCI2 and association with objective
attention measures
Reaction time delays in CRT as well as greater
fluctuations in CRThave been reported inDLB and
PDD (Ballard et al., 2002) and we confirmed this
association and also found significant associations
between DLB-PCI2 expression and CRT and
CRT(SD).
Visuo-perceptual motor tasks have been sug-
gested to decompose into four discrete temporally
ordered elements (Donders, 1869): stimulus detec-
tion, stimulus discrimination, response selection,
and motor execution and it is likely that CRT
reaction time is dependent upon all these factors.
The association between CRT and its variability
with DLB-PCI2 as well as the topographic
alignment of the DLB-PCI2 onto areas affiliated
to perceptual processing (parietal) and motor
processing (SMA, cerebellum, and striatum) may
suggest that these specific processing components
(and their dysfunction) involved in the CRT may
be relatively more important in the etiology of
attentional dysfunction and FC in DLB.
However given we only examined CRT and
CRT(SD) in the present study, we must qualify this
statement with the caveat that it is unclear whether
DLB-PCI2 specifically relates to dysfunction in
this aspect of attention or more broadly to other
attentional components (e.g. vigilance), although
it is notable that CRT and CRT(SD), which
include all components of visuo-perceptual motor
processing and their variability, are the strongest
objective attentional measures which associate with
FC. Therefore, it is likely that the topographic
regions involved in DLB-PCI2 perfusion network
are areas which may have a role in FC in DLB.
Understanding the topography of DLB-PCI2
Evidence for structural connectivity between pre-
SMA/SMA, basal ganglia, and cerebellum provides
a basis to support the observed perfusion covariance
seen between these areas in the DLB-PCI2. The
widespread relative reduction in parietal perfusion
is consistent with observed posterior, parietal EEG
(Bonanni et al., 2008), and resting state network
abnormalities in DLB (Franciotti et al., 2013),
which are known to associate with the severity
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of FC and the putative role these regions have
in attentional function. The relative increases in
the motor system are perhaps more difficult to
explain but might reflect a compensatory activity
in response to a relative cholinergic/dopaminergic
deficit. In addition, while these areas subserve
motor functions (e.g. the fronto-striatal SMA–
putamen motor loop), they also have significant
roles in cognition (Middleton and Strick, 2000).
For example, the pre-SMA, which receives inputs
from the cerebellum and basal ganglia (Akkal et al.,
2007), has been associated with cognition and
attention (e.g. Macar et al., 2006), and functional
disconnection between the prefrontal cortex and the
SMA in PD is associated with impaired attention
to action performance (Rowe et al., 2002). The
SMA may also be particularly pertinent to reaction
time tasks given its putative activation with non-
sequential and stimulus-cued movement (Picard
and Strick, 2003) and its activation in fMRI -related
CRT tasks (Winterer et al., 2002).
PD patients have abnormalities in time
estimation (Pastor et al., 1992) and dopamine-
dependent basal ganglia dysfunction leads to
abnormal temporal processing in the millisecond
to seconds range (so called interval timing) (Jones
et al., 2008) and it is notable that perceptual timing
models include elements of a motor network which
overlaps with DLB-PCI2 such as the cerebellum,
basal ganglia, pre-SMA, and SMA (Macar et al.,
2006; Teki et al., 2011). Therefore, an intriguing
question is whether slowed task reaction time and
its variability, as well as FC in DLB, intrinsically
relate to aberrant processing of time via motor
networks. Further work with task-related functional
neuroimaging would be required to test the veracity
of this hypothesis.
The DLB-PCI2 also included increased mid-
brain (possibly inclusive of superior colliculus) and
medial cerebellar activity with decreased parietal
lobe activity which may hint at dysfunctions in
networks associated with attention shifting/spatial
orienting (Posner et al., 1982; Rafal et al., 1988)
although given the limits of spatial resolution of
SPECT, this can only be a speculative comment.
Surprisingly, we did not see any alteration
in activity within thalamic areas despite prior
clinicopathological and neuroimaging evidences
implicating this area in FC in DLB (O’Brien
et al., 2005; Pimlott et al., 2006; Piggott et al.,
2007). A SCA approach only considers areas which
covary in activity and thus it is feasible that any
absolute perfusion changes related to FCwithin this
structure do not associate with perfusion alterations
elsewhere although it is notable when we carried
out a post hoc univariate region of interest analysis
of thalamic SPECT perfusion and its relationship
to FC, we failed to find any significant correlations
in the present cohort (data not shown).
We also did not see any significant topographic
overlap between DLB-PCI2 and the default mode
network (DMN) which associates with attentional
task performance (Weissman et al., 2006). Part of
this may be due to the fact that our spatial resolution
is lower with SPECT than PET for example, and
thus perhaps activity which appeared localized to
the pre-SMA/SMA may actually have intruded into
the anterior cingulate cortex (ACC), an established
hub in the DMN.However, recent data suggest that
the DMN function is actually preserved in DLB
patients (Franciotti et al., 2013) (even those with
severe FC), thus suggesting that the DMNmay not
be a major player in terms of FC in DLB, although
perhaps other resting state networks, e.g. ventral or
dorsal attention network, might be more salient.
Strengths of the study include the careful
diagnostic work-up of patients, as well as
neuropathologic confirmation in a minority. A
major limitation of the present study is the
lower resolution of SPECT perfusion imaging
in comparison to PET metabolism imaging.
While our covariant networks maintained statistical
robustness, this issue still restricts the spatial
accuracy of delimiting topographic structures
involved in perfusion networks. Finally, it is
important to note that covariant analyses provide
a relativistic measure between different cortical
regions rather than absolute quantification; thus,
it cannot determine which areas or regions in
the network are specifically “normal” versus
“abnormal” in function and how these relate to
the clinical phenotype or symptoms, only that
the overall network pattern itself is intrinsically
associated with these disease features. Nevertheless,
it is clear that multivariate approaches which are
sympathetic to the network dynamics of the brain
offer an additional means by which to examine
pathophysiological processes in DLB.
Conclusions
Using SCA applied to SPECT perfusion imaging,
we provide evidence of a DLB-specific covariant
perfusion network (which presumptively is an
expression of an underlying neural network) that
encompasses bilateral motor areas and the parietal
and parieto-temporal cortices and which are
strongly associated with cognition and FC.
Attentional performance as measured by the
CRT in DLB and FC appears to map onto a
combined motor and cognitive network. While this
network does not explain the cause of FC or
attentional dysfunction in its entirety in DLB, our
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findings suggest a link between FC and cognition
via a combined cognitive-motor network, which in
part might be influenced by distributed cholinergic
dysfunction.
Conflict of interest
None.
Description of authors’ roles
J.-P. Taylor was responsible for the inception of
the research question, study design, data analysis,
and prepared the paper. S. J. Colloby developed
the multivariate analysis approaches and helped
review and revise drafts of the paper. I. G.
McKeith was involved in the patient recruitment,
participant diagnostic rating, and made comments
on the paper. J. T. O’Brien was involved in
the participant recruitment, participant diagnostic
rating, and helped review and revise drafts of the
paper. In addition, he acted as a fellowship sponsor
to J.-P. Taylor.
Acknowledgments
The research was supported by an Interme-
diate Clinical Fellowship to Dr J.-P. Taylor
(WT088441MA) and was funded by the Medical
Research Council, UK (G9817682).
The research was also supported by the National
Institute for Health Research (NIHR) Newcastle
Biomedical Research Unit based at Newcastle
upon Tyne Hospitals NHS Foundation Trust and
Newcastle University. The views expressed are
those of the authors and not necessarily those of
the NHS, the NIHR, or the Department of Health.
References
Aarsland, D., Ballard, C., McKeith, I., Perry, R. H. and
Larsen, J. P. (2001). Comparison of extrapyramidal signs
in dementia with Lewy bodies and Parkinson’s disease. The
Journal of Neuropsychiatry and Clinical Neurosciences, 13,
374–379.
Abe, Y. et al. (2003). Occipital hypoperfusion in Parkinson’s
disease without dementia: correlation to impaired cortical
visual processing. Journal of Neurology Neurosurgery and
Psychiatry, 74, 419–422.
Akkal, D., Dum, R. P. and Strick, P. L. (2007).
Supplementary motor area and presupplementary motor
area: targets of basal ganglia and cerebellar output. Journal
of Neuroscience, 27, 10659–10673.
Asanuma, K. et al. (2006). Network modulation in the
treatment of Parkinson’s disease. Brain, 129, 2667–2678.
Ballard, C., Walker, M., O’Brien, J., Rowan, E. and
McKeith, I. (2001). The characterisation and impact of
“fluctuating” cognition in dementia with Lewy bodies and
Alzheimer’s disease. International Journal of Geriatric
Psychiatry, 16, 494–498.
Ballard, C. G. et al. (2002). Fluctuations in attention: PD
dementia vs DLB with parkinsonism. Neurology, 59,
1714–1720.
Bonanni, L., Thomas, A., Tiraboschi, P., Perfetti, B.,
Varanese, S. and Onofrj, M. (2008). EEG comparisons
in early Alzheimer’s disease, dementia with Lewy bodies
and Parkinson’s disease with dementia patients with a
2-year follow-up. Brain, 131, 690–705.
Bradshaw, J., Saling, M., Hopwood, M., Anderson, V.
and Brodtmann, A. (2004). Fluctuating cognition in
dementia with Lewy bodies and Alzheimer’s disease is
qualitatively distinct. Journal of Neurology Neurosurgery and
Psychiatry, 75, 382–387.
Colloby, S. J. et al. (2002). A comparison of
(99m)Tc-HMPAO SPET changes in dementia with Lewy
bodies and Alzheimer’s disease using statistical parametric
mapping. European Journal of Nuclear Medicine and
Molecular Imaging, 29, 615–622.
Colloby, S. J. et al. (2008). A comparison of
99mTc-exametazime and 123I-FP-CIT SPECT imaging in
the differential diagnosis of Alzheimer’s disease and
dementia with Lewy bodies. International Psychogeriatrics,
20, 1124–1140.
Colloby, S. J. et al. (2013). Multivariate spatial covariance
analysis of 99mTc-exametazime SPECT images in
dementia with Lewy bodies and Alzheimer’s disease: utility
in differential diagnosis. Journal of Cerebral Blood Flow and
Metabolism, 33, 612–618.
Donders, F. C. (1869). On the speed of mental processes. In
W. G. Koster (ed.), Attention and Performance II. Acta
Psychologica, 30, 412–431. (Original work published in
1868.)
Eckert, T., Tang, C. and Eidelberg, D. (2007a).
Assessment of the progression of Parkinson’s disease: a
metabolic network approach. Lancet Neurology, 6, 926–932.
Eckert, T. et al. (2007b). Quantification of Parkinson’s
disease-related network expression with ECD SPECT.
Journal of Nuclear Medicine and Molecular Imaging, 34,
496–501.
Eidelberg, D. et al. (1995). Assessment of disease severity in
Parkinsonism with fluorine-18-fluorodeoxyglucose and
PET. Journal of Nuclear Medicine, 36, 378–383.
Ferman, T. J. et al. (2004). DLB fluctuations: specific
features that reliably differentiate DLB from AD and
normal aging. Neurology, 62, 181–187.
Franciotti, R. et al. (2013). Default network is not
hypoactive in dementia with fluctuating cognition: an
Alzheimer disease/dementia with Lewy bodies comparison.
Neurobiology of Aging, 34, 1148–1158.
Francis, P. T., Perry, E. K., Piggott, M. A. and Duda,
J. E. (2006). Neurochemical pathology of dementia with
Lewy bodies. In J. T. O’Brien, I. G. Mckeith, D. Ames and
E. Chiu (eds.), Dementia with Lewy Bodies and Parkinson’s
Disease Dementia (pp. 167–176). Oxon: Taylor and Francis
Group.
Gene, E. and Alexander, J. R. M. (1994). Application of
the scaled subprofile model to functional imaging in
1928 J.-P. Taylor et al.
neuropsychiatric disorders: a principal component
approach to modeling brain function in disease. Human
Brain Mapping, 2, 79–94.
Habeck, C. et al. (2005). A new approach to spatial
covariance modeling of functional brain imaging data:
ordinal trend analysis. Neural Computing, 17, 1602–1645.
Hirano, S., Eckert, T., Flanagan, T. and Eidelberg, D.
(2009). Metabolic networks for assessment of therapy and
diagnosis in Parkinson’s disease. Movement Disorders, 24
(Suppl. 2), S725–S731.
Huang, C., Mattis, P., Tang, C., Perrine, K., Carbon,
M. and Eidelberg, D. (2007). Metabolic brain networks
associated with cognitive function in Parkinson’s disease.
NeuroImage, 34, 714–723.
Jones, C. R., Malone, T. J., Dirnberger, G., Edwards, M.
and Jahanshahi, M. (2008). Basal ganglia, dopamine and
temporal processing: performance on three timing tasks on
and off medication in Parkinson’s disease. Brain and
Cognition, 68, 30–41.
Kessels, R. P., Mimpen, G., Melis, R. and Rikkert, M. G.
(2009). Measuring impairments in memory and executive
function in older people using the Revised Cambridge
Cognitive Examination. American Journal of Geriatric
Psychiatry, 17, 793–801.
Lozza, C., Baron, J. C., Eidelberg, D., Mentis, M. J.,
Carbon, M. and Marie, R. M. (2004). Executive
processes in Parkinson’s disease: FDG-PET and network
analysis. Human Brain Mapping, 22, 236–245.
Macar, F., Coull, J. and Vidal, F. (2006). The
supplementary motor area in motor and perceptual time
processing: fMRI studies. Cognitive Processing, 7, 89–94.
McKeith, I. G. et al. (1996). Consensus guidelines for the
clinical and pathologic diagnosis of dementia with Lewy
bodies (DLB): report of the consortium on DLB
international workshop. Neurology, 47, 1113–1124.
McKeith, I. et al. (2000). Efficacy of rivastigmine in
dementia with Lewy bodies: a randomised, double-blind,
placebo-controlled international study. Lancet, 356,
2031–2036.
McKeith, I. G. et al. (2005). Diagnosis and management of
dementia with Lewy bodies. Third report of the DLB
consortium. Neurology, 65, 1863–1872.
McKhann, G., Drachman, D., Folstein, M., Katzman,
R., Price, D. and Stadlan, E. M. (1984). Clinical
diagnosis of Alzheimer’s disease: report of the
NINCDS-ADRDA Work Group under the auspices of
Department of Health and Human Services Task Force on
Alzheimer’s disease. Neurology, 34, 939–944.
Mesulam, M.-M. (1981). A cortical network for directed
attention and unilateral neglect. Annals of Neurology, 10,
309–325.
Middleton, F. A. and Strick, P. L. (2000). Basal ganglia
and cerebellar loops: motor and cognitive circuits. Brain
Research Reviews, 31, 236–250.
O’Brien, J. T., Firbank, M. J., Mosimann, U. P., Burn,
D. J. and McKeith, I. G. (2005). Change in perfusion,
hallucinations and fluctuations in consciousness in
dementia with Lewy bodies. Psychiatry Research, 139,
79–88.
Pastor, M. A., Artieda, J., Jahanshahi, M. and Obeso,
J. A. (1992). Time estimation and reproduction is
abnormal in Parkinson’s disease. Brain, 115, 211–225.
Perry, E., Walker, M., Grace, J. and Perry, R. (1999).
Acetylcholine in mind: a neurotransmitter correlate of
consciousness? Trends in Neuroscience, 22, 273–280.
Picard, N. and Strick, P. L. (2003). Activation of the
supplementary motor area (SMA) during performance of
visually guided movements. Cerebral Cortex, 13, 977–986.
Piggott, M. A., Ballard, C. G., Dickinson, H. O.,
McKeith, I. G., Perry, R. H. and Perry, E. K. (2007).
Thalamic D2 receptors in dementia with Lewy bodies,
Parkinson’s disease, and Parkinson’s disease dementia.
International Journal of Neuropsychopharmacology, 10,
231–244.
Pimlott, S. L. et al. (2006). Thalamic nicotinic receptors
implicated in disturbed consciousness in dementia with
Lewy bodies. Neurobiology of Disease, 21, 50–56.
Posner, M. I., Cohen, Y. and Rafal, R. D. (1982). Neural
systems control of spatial orienting. Philosophical
Transactions of the Royal Society of London. Series B Biological
Sciences, 298, 187–198.
Rafal, R. D., Posner, M. I., Friedman, J. H., Inhoff,
A. W. and Bernstein, E. (1988). Orienting of visual
attention in progressive supranuclear palsy. Brain, 111,
267–280.
Rowe, J., Stephan, K. E., Friston, K., Frackowiak, R.,
Lees, A. and Passingham, R. (2002). Attention to action
in Parkinson’s disease: impaired effective connectivity
among frontal cortical regions. Brain, 125, 276–289.
Steriade, M. (2006). Grouping of brain rhythms in
corticothalamic systems. Neuroscience, 137, 1087–1106.
Teki, S., Grube, M. and Griffiths, T. D. (2011). A unified
model of time perception accounts for duration-based and
beat-based timing mechanisms. Frontiers in Integrative
Neuroscience, 5, 90.
Walker, M. P. et al. (2000a). The clinician assessment of
fluctuation and the one day fluctuation assessment scale.
Two methods to assess fluctuating confusion in dementia.
British Journal of Psychiatry, 177, 252–256.
Walker, M. P. et al. (2000b). Quantification and
characterization of fluctuating cognition in dementia with
Lewy bodies and Alzheimer’s disease. Dementia Geriatric
and Cognitive Disorders, 11, 327–335.
Weissman, D. H., Roberts, K. C., Visscher, K. M. and
Woldorff, M. G. (2006). The neural bases of momentary
lapses in attention. Nature Neuroscience, 9, 971–978.
Wesnes, K. A. et al. (2002). Effects of rivastigmine on
cognitive function in dementia with Lewy bodies: a
randomised placebo-controlled international study using
the cognitive drug research computerised assessment
system. Dementia Geriatric and Cognitive Disorders, 13,
183–192.
Whitwell, J. L. et al. (2007). Focal atrophy in dementia with
Lewy bodies on MRI: a distinct pattern from Alzheimer’s
disease. Brain, 130, 708–719.
Winterer, G., Adams, C. M., Jones, D. W. and Knutson,
B. (2002). Volition to action – an event-related fMRI
study. NeuroImage, 17, 851–858.
